PURPOSE: To assess treatment effects following intravitreal injection of ocriplasmin for vitreomacular traction (VMT), with or without full-thickness macular hole (FTMH), in real-life setting. METHODS: This is a monocentric, retrospective, consecutive series of 82 eyes from 82 patients who underwent ocriplasmin treatment between July 2013 and December 2016. We included 57 eyes with pure VMT, 17 eyes with small FTMHs, and eight eyes with medium FTMHs. Primary outcome measures were VMT release and MH closure rates. Secondary outcomes were visual acuity (VA), morphological changes, and subjective visual impairment after 1, 3, and 6 months and at last follow-up. RESULTS: After a median follow-up of 10 months, VMT release was achieved by pharmacologic vitreolysis in 57% of all eyes, whereas the macular hole closure rate was 32%. In those presenting with five or more positive prognostic factors (PPF), eyes with pure VMT showed nonsurgical traction release in 88%, and FTMHs were released in 93%, with a closure rate of 20%. Small FTMHs closed in 41% and medium FTMHs in 13%. The mean change in VA (LogMAR) was -0.07 ± 0.24 (median - 0.10) in all eyes. Subretinal fluid accumulation and ellipsoid zone changes were seen in 31% and 37% of all eyes, respectively. They were more frequent in eyes with traction release, but were self-limited. CONCLUSIONS: In a real-life setting, release of VMT by ocriplasmin injection can be achieved in the majority of eyes, relying on a strict patient selection. Closure of FTMHs rather correlates with hole diameter than with presence of PPF, and remains a rare finding in medium FTMHs.
PURPOSE: To assess treatment effects following intravitreal injection of ocriplasmin for vitreomacular traction (VMT), with or without full-thickness macular hole (FTMH), in real-life setting. METHODS: This is a monocentric, retrospective, consecutive series of 82 eyes from 82 patients who underwent ocriplasmin treatment between July 2013 and December 2016. We included 57 eyes with pure VMT, 17 eyes with small FTMHs, and eight eyes with medium FTMHs. Primary outcome measures were VMT release and MH closure rates. Secondary outcomes were visual acuity (VA), morphological changes, and subjective visual impairment after 1, 3, and 6 months and at last follow-up. RESULTS: After a median follow-up of 10 months, VMT release was achieved by pharmacologic vitreolysis in 57% of all eyes, whereas the macular hole closure rate was 32%. In those presenting with five or more positive prognostic factors (PPF), eyes with pure VMT showed nonsurgical traction release in 88%, and FTMHs were released in 93%, with a closure rate of 20%. Small FTMHs closed in 41% and medium FTMHs in 13%. The mean change in VA (LogMAR) was -0.07 ± 0.24 (median - 0.10) in all eyes. Subretinal fluid accumulation and ellipsoid zone changes were seen in 31% and 37% of all eyes, respectively. They were more frequent in eyes with traction release, but were self-limited. CONCLUSIONS: In a real-life setting, release of VMT by ocriplasmin injection can be achieved in the majority of eyes, relying on a strict patient selection. Closure of FTMHs rather correlates with hole diameter than with presence of PPF, and remains a rare finding in medium FTMHs.
Authors: Margaret A Greven; Sunir Garg; Bing Chiu; Sumit P Shah; Jeremy Wolfe; Howard F Fine; Daniel B Roth; Joshua Robinson; Jacob Mong; Jason Hsu; Carl Regillo; Allen Ho; Julia A Haller Journal: Br J Ophthalmol Date: 2015-12-09 Impact factor: 4.638
Authors: João Figueira; David Martins; Bernardete Pessoa; Natália Ferreira; Angelina Meireles; António Sampaio; Ângela Carneiro; Fernanda Vaz; João Nascimento; Natacha Moreno; José Roque; Manuel Domingues; Rita Flores; Carla Teixeira; Eduardo Conde; Filipe Henriques; Helena Proença; José Pita Negrão; Marisa Barbosa; Rufino Silva; Sara Vaz-Pereira; Pedro Pereira Neves; Nuno Gomes; Miguel Raimundo Journal: Ophthalmic Res Date: 2016-07-20 Impact factor: 2.892
Authors: Marc D de Smet; Christophe Valmaggia; Javier Zarranz-Ventura; Ben Willekens Journal: Invest Ophthalmol Vis Sci Date: 2008-09-20 Impact factor: 4.799
Authors: Arnd Gandorfer; Matthew S Benz; Julia A Haller; Peter Stalmans; Stephen J Pakola; Aniz Girach; Anselm Kampik; Cynthia A Toth; Glenn J Jaffe Journal: Retina Date: 2015-06 Impact factor: 4.256
Authors: Ricarda G Schumann; Armin Wolf; Hans Hoerauf; Albrecht Lommatzsch; Mathias Maier; Joachim Wachtlin; Michael J Koss; Thomas Kreutzer; Thomas Bertelmann; Sara Kazerounian; Stefan Mennel; Siegfried G Priglinger Journal: Retina Date: 2017-12 Impact factor: 4.256
Authors: David H W Steel; Niall Patton; Theodor Stappler; Niral Karia; Hans Hoerauf; Nishal Patel; Joachim Wachtlin; Thomas Raber; Petra Kozma-Wiebe Journal: Retina Date: 2021-02-01 Impact factor: 3.975